Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Max Strength Mucinex Sales Could Reach $70M In Debut Season – Adams

This article was originally published in The Tan Sheet

Executive Summary

Adams Respiratory Therapeutics projects sales of its forthcoming Maximum Strength Mucinex products will eventually make up 60 percent of total Mucinex sales, the firm said April 4
Advertisement

Related Content

Reckitt Raises Guidance On Adams Performance, Marketing Momentum
Reckitt Raises Guidance On Adams Performance, Marketing Momentum
Reckitt Raises Guidance On Adams Performance, Marketing Momentum
Adams May Cough Up Humibid As Product Confusion Congests Sales
Adams May Cough Up Humibid As Product Confusion Congests Sales
Adams Faces Another Mucinex Challenge, Prepares For Product Launches
Adams Revenue Grows 11% As Mucinex Sales Shift Toward Line Extensions
Sales & Earnings In Brief
Adams Expands OTC Cough Market Presence With Delsym Acquisition
Adams Expands OTC Cough Market Presence With Delsym Acquisition

Topics

Advertisement
UsernamePublicRestriction

Register

PS100383

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel